A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

March 14, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

October 31, 2029

Conditions
X-Linked Retinitis Pigmentosa
Interventions
BIOLOGICAL

rAAV2tYF-GRK1-hRPGRco

Adeno-associated virus vector expressing a human RPGR gene

DRUG

Control

Untreated Control Group 3

Trial Locations (24)

2000

Sydney Eye Hospital, Sydney

3002

Royal Victorian Eye & Ear Hospital, East Melbourne

15219

University of Pittsburgh, Pittsburgh

19104

The Center for Advanced Retinal & Ocular Therapeutics University of Pennsylvania Perelman School of Medicine, Philadelphia

19107

Mid Atlantic Retina, Philadelphia

21287

Wilmer Eye Institute at Johns Hopkins, Baltimore

27710

Duke Eye Center, Durham

32209

University of Florida Health Jacksonville, Department of Ophthalmology, Jacksonville

33136

Bascom Palmer Eye Institute- University of Miami, Miami

44195

Cole Eye Institute - Cleveland Clinic, Cleveland

45242

Cincinnati Eye Institute, Cincinnati

46290

Midwest Eye Institute (Retina Partners Midwest), Carmel

55905

Mayo Clinic, Rochester

75231

Retina Foundation of the Southwest, Dallas

77030

Baylor Eye Institute, Houston

77401

Retina Consultants of Texas, Bellaire

78240

Retina Consultants of San Antonio Texas, San Antonio

85255

Retina Macula Institute of Arizona, Scottsdale

90027

Children's Hospital Los Angeles, Los Angeles

97239

Casey Eye Institute, OHSU, Portland

02114

Ophthalmic Consultants of Boston, Boston

EC1V 2PD

Moorfields Eye Hospital, London

W1G7LB

The Retina Clinic London, Institute of Ophthalmology, University College London, London

OX39DU

Oxford Eye Hospital, Oxford

Sponsors
All Listed Sponsors
lead

Beacon Therapeutics

INDUSTRY